[HTML] sciencedirect.com

[HTML][HTML] The ublituximab-umbralisib (U2) drug regimen potentiates the activity of the novel CD47-CD19 bispecific antibody, TG-1801, through the activation of the G …

E Normant, ML Ribeiro, N Profitos-Peleja, P Blecua… - Blood, 2021 - Elsevier
Introduction: TG-1801 is a novel, bispecific anti-CD47 and anti-CD19 fully human IgG1
antibody that targets CD47 selectively on CD19+ B-cells, sparing red blood cells or platelets …
被引用次数：8 相关文章

The Ublituximab-Umbralisib (U2) Drug Regimen Potentiates the Activity of the Novel CD47-CD19 Bispecific Antibody, TG-1801, through the Activation of the G Protein …

E Normant, ML Ribeiro, N Profitos-Peleja, P Blecua… - Blood, 2021 - ashpublications.org
Introduction: TG-1801 is a novel, bispecific anti-CD47 and anti-CD19 fully human IgG1
antibody that targets CD47 selectively on CD19+ B-cells, sparing red blood cells or platelets …